At the highest dose tested, Vaxcyte’s shot elicited a stronger immune response against 18 of the 20 strains compared with ...

Pfizer and Germany’s Merck have announced that their PD-L1 checkpoint inhibitor avelumab has been accepted for filing by the FDA, setting up the partners to join the fast-expanding cancer ...

Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab ...

Pfizer's recent financial performance shows 14% YoY operational growth excluding COVID sales. Check out more on PFE stock ...

An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP. [Reuters] Rival antiviral pills from Pfizer Inc and Merck & Co ...

Merck MRK announced that a phase study evaluating its Daiichi Sankyo-partnered HER3-directed DXd antibody drug conjugate (ADC ...

Merck ( MRK 0.53%) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

AbbVie, Merck, Bristol Myers Squibb, and Pfizer are the latest beneficiaries of the "Buffett Effect." The quartet of pharmaceutical stocks jumped in pre-market trading on Tuesday after Warren ...

AbbVie is a Dividend King with solid growth prospects. Merck's looming patent cliff isn't as alarming as it might seem. Pfizer offers a high dividend yield and lots of upside potential.

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck ...